BioNexus Gene Lab Corp
Close on Oct 19, 2026
- Market cap
- $2.97M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
BioNexus Gene Lab has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements BioNexus Gene Lab filed with the SEC
BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
Other events · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
Other events · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of its VitaGuard™ MRD Platform
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
Other events · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology
Regulation FD disclosure · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy
Regulation FD disclosure · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper
Other events · EX-99.1 to Form 8-K
BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.
Material agreement · Other events · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.
Regulation FD disclosure · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production
Regulation FD disclosure · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions
Regulation FD disclosure · EX-99.2 to Form 8-K
BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd
Regulation FD disclosure · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K